Well-known big three A executive pharmaceutical representatives for the record.

Recently, the national third-level A-level general hospital Chengdu Fifth People's Hospital held a drug distribution enterprise integrity interview.
It is understood that, in order to deeply implement the "2020 to correct the field of pharmaceutical purchase and sale and medical services in the field of the wrong wind work points" requirements, a consistent, unswerving "management industry must manage the wind" "who is in charge of who is responsible" of the governance requirements into practice, for the pharmaceutical purchase and sale of the field and medical services to clear the red line of behavior, the formation of a clean new wind in the industry, Chengdu Fifth People's Hospital in the East District Academic Hall held a hospital drug distribution business meeting. the
notice shows that on the recent higher authorities issued a number of outstanding problems in the field of rectification of the industry, the spirit of the special rectification work has been announced, focusing on the pharmaceutical business distribution enterprises clean self-examination and self-correction, pharmaceutical representative filing system implementation, drug business compliance and compliance with the law and other acts stressed.
addition, the Vice President on the recent hospital health industry in the field of outstanding issues of special rectification work, focusing on the "big prescriptions, pan-consumables" and other issues of supervision, medical representatives registration and filing system was notified.
from this official notice, the medical representative filing system in this big three official landing.
And according to industry media reports, Chengdu Fifth People's Hospital requires all medical representatives who carry out professional activities in the hospital must fill out and report the "Pharmaceutical Representative Filing Information Form" by September 21, 2020 to complete the relevant information for the record.
Filing requirements: 1, pharmaceutical business enterprises for the record of pharmaceutical representatives shall not exceed 2 people; 2, pharmaceutical production enterprises for the record of pharmaceutical representatives of each variety shall not exceed 1 person; 3, pharmaceutical enterprises are responsible for collecting corresponding distribution varieties of production enterprises pharmaceutical representatives for the record information form, after strict examination to complete the "pharmaceutical representatives registration form" completed; 4. Those who have not completed the record within the prescribed time shall not carry out relevant business activities in the hospital, and all units shall be invited to attach great importance to it, and the consequences of overdue shall be at their own risk; 5. Pharmaceutical enterprises shall be responsible for the authenticity and accuracy of the information available (including the production enterprises); and 6. If in doubt, please contact the treasury in a timely manner.
Seber Blue combed through the medical representative's filing information form and found that the information form mainly includes the representative's name, gender, photo, document number, education, profession, industry category and other basic information, but also the pharmaceutical sales of the representative's pharmaceutical production /business enterprise name, unified social credit code, contract start date/termination date, authorized promotion of the drug category and treatment field and other details related to the promotion of the representative.
In addition, it is worth noting that the information form also requires the pharmaceutical production/business organization it represents to make a statement on the authenticity of the information - the unit (or individual) to ensure that the above content does not contain any false information, and the above content of the authenticity, accuracy of full responsibility.
the information form, a medical representative's credit history is required.
To some extent, the relevant information of pharmaceutical representatives and pharmaceutical enterprises are all registered in the table, whether it is the promotion of product information, or the credit history of pharmaceutical representatives themselves, are in the hands of the hospital, but also to the medical representatives to medical personnel illegal marketing restrictions.
the filing system, when will it be implemented? Indeed, one of the documents that has had the greatest impact on pharmaceutical representatives so far this year is the Measures for the Administration of the Filing of Pharmaceutical Representatives (Trial) (Draft for Comments), issued on June 5th, which provides for the academic promotion of pharmaceutical representatives.
The Measures state that medical representatives may carry out academic promotion and other activities in the following forms: (1) to communicate with medical personnel in person in medical institutions; (2) to hold academic conferences and lectures; (3) to provide academic materials; (4) to communicate through the Internet or teleconsescing; and (5) to communicate in other forms agreed by medical institutions.
is a clear signal that the management and regulation of pharmaceutical representatives has been put on the agenda at the national level, but also means that the pharmaceutical representative filing system is getting closer and closer in the country.
Article 14 of the document makes it clear that pharmaceutical representatives shall not carry out academic promotion activities without the consent of medical institutions, undertake the task of drug sales, collect funds and process purchase and sell bills, participate in the counting of the number of drug prescriptions issued by individual doctors, directly provide donations and sponsorship to departments and individuals in medical institutions, mislead doctors about the use of drugs, exaggerate or mislead efficacy, conceal information about known adverse reactions of drugs or conceal adverse reactions of doctors' feedback.
The moment the filing system is launched, it means that the work of pharmaceutical representatives will begin to become transparent and a certain system of disciplinary action for disrelition will be established, and once "crossing the line" will be blacklisted and punished directly with pharmaceutical companies, there will be no longer the term "personal conduct".
industry has told Cypress Blue, pharmaceutical representative filing system will gradually land next, the introduction of detailed documents.
the first step since the release of the well-known big three to implement the filing system.
That is to say, with the promotion of the filing system, the future pharmaceutical representatives must be transformed with the direction of the national medical reform policy, can not rely on the way of customer and gold, but through the real compliance of academic promotion, as well as online and offline three-dimensional academic conferences and activities to promote their products.
.